Parkinson’s Disease Therapeutics Market to Reach USD 13.34 Billion by 2034 Driven by Aging Population and Innovative Therapies

Precedence Research reports that the global Parkinson’s disease therapeutics market size is projected to grow from USD 6.59 billion in 2024 to USD 13.34 billion by 2034, expanding at a CAGR of 7.39% between 2025 and 2034. The market’s momentum is driven by the rapid aging of the global population, continuous innovation in drug discovery, and the rising adoption of infusion-based and wearable therapies.

Parkinson’s Disease Therapeutics Market Overview

Parkinson’s disease (PD) is one of the most common neurodegenerative disorders, caused by dopamine deficiency and characterized by motor and non-motor symptoms including tremors, stiffness, postural instability, bradykinesia, and sleep issues. While traditional drug classes such as levodopa/carbidopa, dopamine agonists, MAO-B inhibitors, and COMT inhibitors remain the backbone of therapy, the market is experiencing a paradigm shift.

A growing emphasis on advanced infusion systems, deep brain stimulation, and supportive therapies such as physiotherapy and occupational therapy is changing the treatment landscape, offering more holistic care for patients.

Parkinson’s Disease Therapeutics Market Quick Points:

• In terms of revenue, the worldwide parkinson’s disease therapeutics market is projected to reach over USD 7.49 billion in 2024.
• It is projected to reach USD 12.35 billion by 2033.
• The market is expected to expand at a strong CAGR of 7.39% from 2025 to 2034.
• North America accounted for the highest market share of 34.60% in 2024.
• Europe is growing at the fastest CAGR from 2025 to 2034.
• By drug class, the levodopa/carbidopa segment held the major market share of 50.93% in 2024.
• By drug class, the COMT inhibitors segment is expected to grow at the fastest CAGR during the forecast period.
• By route of administration, the oral segment accounted for the biggest market share of 63.18% in 2024.
• By patient, the adult segment held the largest market share of 84.89% in 2024.

Parkinson’s Disease Therapeutics Market Size Analysis (USD Million) 2021 to 2023

Parkinson’s Disease Therapeutics Market Size Analysis (USD Million) By Drug Class 2021 to 2023

Parkinson’s Disease Therapeutics Market Size Analysis (USD Million) By Route of Administration 2021 to 2023

Parkinson’s Disease Therapeutics Market Size Analysis (USD Million) By Route of Administration 2021 to 2023

The Full Study is Readily Available | Download the Sample Pages of this Report@ https://www.precedenceresearch.com/checkout/4430

Top Therapeutics for Parkinson’s Disease

Who are the Leading Exporters of Levodopa?

Parkinson’s Disease Therapeutics Market Emerging Trends

The future of Parkinson’s care is being reshaped by innovation. Drug–device combinations are gaining traction, with wearable infusion pumps providing continuous delivery of therapies such as apomorphine—significantly reducing “off episodes” for patients. In 2025, Supernus Pharmaceuticals gained FDA approval for ONAPGO, a subcutaneous apomorphine infusion device designed to deliver 24-hour symptom control, marking a milestone in the U.S. market. Similarly, AbbVie’s Produodopa launch in Europe in 2024 reflects the industry’s growing shift toward infusion-based therapies.

Other promising advancements include selective dopamine receptor agonists (targeting D1/D5 receptors), gene therapy approaches, and the integration of precision medicine—allowing treatments to be tailored to patient genetics for improved efficacy and safety. Wearable monitoring devices, AI-driven drug discovery, and mobile app integrations are also emerging, creating opportunities for earlier diagnosis and improved patient outcomes.

Parkinson’s Disease Therapeutics Market Opportunity and Challenges

The market opportunity is immense, supported by rapid demographic changes and technological innovation. An aging global population will continue to drive demand, while developments in deep brain stimulation, focused ultrasound, nanomedicine, and telehealth are opening new treatment pathways.

However, challenges remain. Long-term use of levodopa is associated with complications such as dyskinesia and hallucinations, while other PD drugs may cause side effects including fatigue, constipation, and compulsive behaviors. These limitations highlight the pressing need for next-generation therapies that balance effectiveness with improved safety profiles.

Also Read@ OTC Drugs Market on the Rise: How Self-Care and E-Commerce Are Shaping a $242.9 Billion Future

Parkinson’s Disease Therapeutics Market Segments Outlook

The Parkinson’s disease therapeutics market can be segmented by drug class, route of administration, and patient demographics, each highlighting unique demand patterns and growth opportunities.

By Drug Class Outlook:

Levodopa/carbidopa remains the cornerstone of Parkinson’s treatment, accounting for more than 50% of the global market in 2024. Its dominance is attributed to its effectiveness in managing primary motor symptoms, making it the gold standard therapy. However, as patients develop long-term complications such as dyskinesia, the reliance on adjunctive therapies is increasing. COMT inhibitors are expected to record the fastest growth over the next decade, supported by their ability to prolong the effects of levodopa and help reduce motor fluctuations.

Similarly, dopamine agonists and MAO-B inhibitors continue to play a strong role in early-stage and maintenance therapy, while adenosine A2A antagonists and glutamate antagonists are expanding treatment portfolios with targeted approaches. The diversification across drug classes reflects the need for personalized therapy tailored to patient progression and symptom variability.

By Route of Administration Outlook:

Oral formulations continue to dominate the market, capturing 63.18% of global revenue in 2024. The popularity of oral therapies is linked to patient familiarity, ease of administration, and availability in multiple forms such as immediate-release tablets and extended-release capsules. However, a notable shift is underway toward non-oral delivery systems. Transdermal formulations, such as patches offering consistent and controlled drug release, are witnessing rapid adoption as they minimize gastrointestinal side effects and improve adherence.

Likewise, subcutaneous therapies are emerging as crucial for advanced-stage patients who require continuous infusion systems for symptom stabilization. These new delivery routes highlight the growing emphasis on patient convenience and minimizing fluctuations in symptom control.

By Patient Demographics Outlook:

Adults represent the overwhelming majority of Parkinson’s patients, accounting for 84.89% of the market in 2024. The rising prevalence among individuals aged 60 and above makes this demographic the primary growth driver for the global market. However, the pediatric segment, though comparatively smaller, is increasingly recognized for its unmet medical needs.

Cases of early-onset and juvenile Parkinsonism, often linked to genetic mutations, are creating demand for more specialized treatment options. As research progresses in precision medicine and genetic therapies, the pediatric segment is expected to gain greater attention over the forecast period.

Parkinson’s Disease Therapeutics Market Regional Outlook

The Parkinson’s disease therapeutics market demonstrates diverse growth patterns across key geographies, shaped by demographic trends, healthcare infrastructure, and regulatory landscapes.

North America:

North America dominated the global market in 2024, led by the United States which accounted for USD 2.28 billion in 2025 and is projected to reach nearly USD 4.25 billion by 2034. Growth in this region is supported by an aging population, advanced healthcare infrastructure, and substantial investments in R&D. The U.S. market benefits from the presence of leading pharmaceutical companies such as AbbVie, Acorda Therapeutics, and Amneal Pharmaceuticals, alongside robust clinical trial pipelines. Additionally, strong insurance coverage and high diagnosis rates ensure broad access to existing therapies. Canada also contributes significantly, with government-backed healthcare initiatives improving access to novel therapies.

Europe:

Europe is set to be the fastest-growing regional market over the forecast period. Countries such as Germany, the UK, France, and Italy are at the forefront, with their strong emphasis on research and supportive government policies. In January 2024, AbbVie’s approval of Produodopa in the EU exemplified the region’s proactive regulatory environment. Rising awareness campaigns and growing healthcare expenditure are further contributing to patient engagement and diagnosis rates. The increasing adoption of non-invasive delivery methods and government funding for neurological disorders are positioning Europe as a hotspot for next-generation Parkinson’s therapeutics.

Asia-Pacific:

Asia-Pacific represents one of the most promising growth frontiers, largely due to its rapidly aging population. Japan and China lead the region, with Japan experiencing one of the highest Parkinson’s prevalence rates worldwide. The availability of generic drugs, government-driven awareness initiatives, and increasing research partnerships with global pharmaceutical companies are strengthening market prospects. India, meanwhile, is emerging as a key exporter of levodopa, underscoring the region’s role not only as a consumer but also as a supplier of essential drugs. Rising disposable incomes and expanding healthcare access in countries such as South Korea, Thailand, and India are expected to drive steady growth through 2034.

Latin America:

Latin America, led by Brazil and Mexico, is showing increasing demand for Parkinson’s therapeutics as awareness about neurodegenerative disorders expands. While healthcare infrastructure remains uneven, growing investment in hospital facilities and access to affordable generic medications are helping the region gain traction. Public health campaigns and partnerships with international players are expected to further strengthen market penetration over the next decade.

Middle East & Africa:

Although still at a nascent stage, the Parkinson’s disease therapeutics market in the Middle East & Africa is gradually expanding. Wealthier nations such as Saudi Arabia and the UAE are investing heavily in healthcare modernization, improving access to advanced therapies. South Africa is emerging as a focal point within sub-Saharan Africa due to its relatively higher prevalence of neurological disorders and increasing investment in medical infrastructure. The gradual rollout of specialized treatment centers and growing collaborations with multinational pharmaceutical companies are anticipated to drive regional growth.

Parkinson’s Disease Therapeutics Market – Key Players Ecosystem Analysis

The Parkinson’s disease therapeutics market is highly competitive and innovation-driven, with a diverse ecosystem of global pharmaceutical giants, biotechnology innovators, medical device developers, and specialized therapy providers. This ecosystem is defined by strategic collaborations, product launches, and research initiatives aimed at addressing the unmet needs of Parkinson’s patients.

1. Global Pharmaceutical Leaders

Companies such as Novartis AG, Merck & Co., Inc., GlaxoSmithKline (GSK), AbbVie Inc., and Teva Pharmaceutical Industries Ltd. dominate the market through their established portfolios of Parkinson’s medications.

• AbbVie is a front-runner with its long-standing dominance in levodopa/carbidopa therapies and recent infusion-based solutions such as Produodopa in the EU.

• Teva leverages its strength in generic medicines, ensuring widespread access to affordable Parkinson’s drugs across both developed and emerging markets.

• Novartis and GSK continue to expand their neurology pipelines, investing in R&D collaborations to explore disease-modifying therapies and next-generation delivery mechanisms.

• Merck is enhancing its neuroscience research capabilities, focusing on long-term innovation that may include gene therapies and precision medicine approaches.

These companies form the core of the ecosystem, ensuring market stability while funding large-scale clinical trials to bring novel drugs to market.

2. Biotechnology Innovators

Biotech firms are key disruptors in the Parkinson’s space, introducing niche therapies and cutting-edge innovations.

• Cerevel Therapeutics focuses on neuroscience drug development, with pipeline candidates targeting dopamine receptor agonists and novel treatment pathways.

• Olatec Therapeutics and Biotech Ltd are exploring experimental compounds that aim to address neuroinflammation and disease modification, areas with significant unmet needs.
  These firms often partner with larger pharmaceutical players for commercialization, bridging the gap between early innovation and large-scale market adoption.

3. Device and Drug–Device Convergence Specialists

A new category of players is emerging around drug–device hybrids and infusion technologies.

• Supernus Pharmaceuticals, Inc. gained FDA approval in 2025 for ONAPGO, a subcutaneous apomorphine infusion device, marking a milestone in wearable, continuous Parkinson’s treatment.

• Such companies are redefining Parkinson’s care by offering alternatives to oral medications and expanding into patient-centric, technology-enabled therapies.
  This shift demonstrates how medical devices are becoming integral to the pharmaceutical ecosystem, enabling more personalized and consistent symptom management.

4. Specialized Therapy Providers

Firms like Hallamshire Physiotherapy Ltd play a supportive role in the broader ecosystem by offering physiotherapy and rehabilitation services. These providers contribute to non-pharmacological management of Parkinson’s, complementing drug therapy with interventions that improve mobility, balance, and quality of life.

5. Regional and Generic Manufacturers

Companies such as Amneal Pharmaceuticals LLC are strengthening their presence by providing cost-effective generics and extended-release formulations of widely used drugs like levodopa. By improving accessibility, particularly in price-sensitive markets such as Asia-Pacific and Latin America, these players ensure Parkinson’s therapies reach a wider patient base.

Competitive Dynamics

The competitive ecosystem is characterized by:

• Innovation pipelines: A strong focus on developing disease-modifying drugs, selective dopamine receptor agonists, and long-acting infusion therapies.

• Strategic partnerships: Collaborations between large pharma and biotech firms to accelerate clinical trials and commercialization of next-generation therapies.

• Market diversification: Movement beyond oral medications into subcutaneous pumps, transdermal patches, and wearable infusion devices.

• Global accessibility: Expanding generic manufacturing to meet rising demand in emerging economies while maintaining premium therapies in developed markets.

Ecosystem Outlook

The Parkinson’s disease therapeutics ecosystem is moving from a pharma-dominated landscape toward a multidisciplinary structure that integrates biotech innovation, device technology, and supportive therapy providers. Pharmaceutical giants provide financial muscle and market reach, biotech companies inject disruptive innovation, device makers introduce patient-centric delivery models, and therapy providers deliver holistic care.

This evolving ecosystem positions the market for sustained growth, with the most successful players expected to be those that combine advanced science with accessibility, convenience, and patient-focused solutions.

• Author
• Recent Posts

Rohan

Principal Consultant at Market Stats Insight

Rohan Patil is a seasoned Healthcare Principal Consultant at Market Stats Insight and Precedence Research, with more than 5 years of experience in market intelligence and strategic insights. Holding a BSc in Biotechnology and an MBA in Marketing, he combines scientific expertise with business acumen to deliver data-driven analysis. Rohan specializes in the medical device sector and closely tracks innovations shaping the future of healthcare. His research helps global clients identify growth opportunities, assess risks, and stay competitive in a rapidly evolving market landscape.

Latest posts by Rohan (see all)

• Next-Generation RNA Therapeutics Market: Transforming Drug Discovery and Precision Medicine - August 29, 2025
• Call of Duty Servers Face Outages as Players Report Connectivity Issues - August 29, 2025
• Google Gmail Data Breach Exposes 2.5 Billion Accounts in Massive Cyberattack - August 29, 2025